Sure coppertop,
From the 14th Nov ann.
The probability of observing this combined degree of clinical benefit
both in the group level and subject -level analyses and no clinically
significant worsening in any endpoint purely by chance (the “false -
positive” rate) as determined as 2.3% (p=0.023) by permutation testing.
In the permutation testing,randomly simulated allocations of patients to NNZ- 2566 and placebo were repeated 1000 times and positive outcomes
in the data were counted. The statistical approach used in the analysis of the trial results, including permutation testing, has been published in a peer-reviewed journal and used in previous trials in other therapeutic areas, including for the development of a product recently granted Breakthrough Therapy designation by the FDA
- Forums
- ASX - By Stock
- NEU
- Ann: Investor Presentation, 8 January 2015
Ann: Investor Presentation, 8 January 2015, page-37
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.59 |
Change
0.070(0.45%) |
Mkt cap ! $1.992B |
Open | High | Low | Value | Volume |
$15.75 | $15.80 | $15.37 | $6.881M | 441.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 35 | $15.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.64 | 2103 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 35 | 15.580 |
2 | 2403 | 15.510 |
3 | 2584 | 15.480 |
1 | 2103 | 15.450 |
1 | 2103 | 15.430 |
Price($) | Vol. | No. |
---|---|---|
15.640 | 2103 | 1 |
15.670 | 2103 | 1 |
15.690 | 2103 | 1 |
15.700 | 40 | 1 |
15.710 | 3000 | 1 |
Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |